The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment
Authors
Keywords
-
Journal
Breast Journal
Volume 18, Issue 1, Pages 41-51
Publisher
Wiley
Online
2011-11-21
DOI
10.1111/j.1524-4741.2011.01175.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer
- (2017) L. A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer
- (2017) A. Tutt et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).
- (2017) J. Crown et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary systemic chemotherapy with carboplatin AUC 6 and docetaxel 75 mg/m2 (q3w) in triple-negative early breast cancer.
- (2017) P. Kern et al. JOURNAL OF CLINICAL ONCOLOGY
- A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).
- (2017) J. O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- The comparison of the benefits obtained from platinum-containing chemotherapy between triple-negative and non-triple-negative metastatic breast cancer.
- (2017) T. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC).
- (2017) J. Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin and its potential in the treatment of soft tissue sarcoma
- (2016) J Fayette Therapeutics and Clinical Risk Management
- A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer
- (2011) M. N. Fornier et al. ANNALS OF ONCOLOGY
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.
- (2010) RS Finn et al. CANCER RESEARCH
- Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies.
- (2010) HS Rugo et al. CANCER RESEARCH
- Heterogeneity of Triple Negative Breast Cancer (TNBC): TNBC Might Be Divided into Two or More Subgroups by Clinicopathologic Findings.
- (2010) Y. Park et al. CANCER RESEARCH
- Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer
- (2010) Chris Twelves et al. Clinical Breast Cancer
- Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer
- (2009) G. Frasci et al. ANNALS OF ONCOLOGY
- Survival among women with triple receptor-negative breast cancer and brain metastases
- (2009) S. Dawood et al. ANNALS OF ONCOLOGY
- Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
- (2009) B. Corkery et al. ANNALS OF ONCOLOGY
- Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers
- (2009) Sharon Nofech-Mozes et al. BREAST CANCER RESEARCH AND TREATMENT
- Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years
- (2009) J. M. Dolle et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design
- (2009) Farrah Kassam et al. Clinical Breast Cancer
- Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
- (2009) E. A. Rakha et al. CLINICAL CANCER RESEARCH
- Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes
- (2009) T. J. Gaymes et al. HAEMATOLOGICA
- Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study
- (2009) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
- (2009) E. Caldas-Lopes et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Platinum-based chemotherapy in triple-negative breast cancer
- (2008) B. Sirohi et al. ANNALS OF ONCOLOGY
- The prognostic importance of triple negative breast carcinoma
- (2008) Hakan Mersin et al. BREAST
- Impact of Triple Negative Phenotype on Breast Cancer Prognosis
- (2008) Henry G. Kaplan et al. Breast Journal
- Early onset of breast cancer in a group of British black women
- (2008) R L Bowen et al. BRITISH JOURNAL OF CANCER
- Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer
- (2008) Nancy U. Lin et al. CANCER
- High prevalence of triple-negative tumors in an urban cancer center
- (2008) Mary Jo B. Lund et al. CANCER
- What is triple-negative breast cancer?
- (2008) William J. Irvin et al. EUROPEAN JOURNAL OF CANCER
- How basal are triple-negative breast cancers?
- (2008) François Bertucci et al. INTERNATIONAL JOURNAL OF CANCER
- Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy
- (2008) Ji Eun Uhm et al. INTERNATIONAL JOURNAL OF CANCER
- Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers
- (2008) Yoshinari Ogawa et al. International Journal of Clinical Oncology
- Dose-Dense and/or Metronomic Schedules of Specific Chemotherapies Consolidate the Chemosensitivity of Triple-Negative Breast Cancer: A Step Toward Reversing Triple-Negative Paradox
- (2008) Rita S. Mehta JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2008) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
- (2008) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Triple Receptor–Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes
- (2008) Shaheenah Dawood et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors
- (2008) E. Rivera et al. ONCOLOGIST
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Is triple negative a prognostic factor in breast cancer?
- (2008) Reiki Nishimura et al. Breast Cancer
- Clinicopathologic and Prognostic Characteristics of Triple-Negative Breast Cancer
- (2008) Xing-song Tian et al. Oncology Research and Treatment
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started